Outcome after CD19.CAR-VST infusions in patients infused with disease. Panels A-F represent single patients. Panels A-C illustrate patients with sustained objective clinical response, and panels D-F illustrate patients with transient or no response. In all panels, black arrows denote the time of CD19.CAR-VST infusions, black circles indicate the detection of CD19.CAR-VSTs in the PB by Q-PCR, and red triangles represent the values of normal B-cell counts in the PB. (A) Data from patient 1. Detection of bcr/abl transcripts are indicated as light gray squares. The gray arrow indicates the increase in dose of dasatinib (TKI). (B-C) Data from patients 2 and 3, respectively. In both subjects, circulating B-CLL cells (CD19⁺CD5⁺) were measured by flow cytometry and are shown as light gray squares. (D-F) Data from patients 4, 5, and 6, respectively. Leukemic cells, measured in the PB by flow cytometry, are represented as light gray squares. The star indicates the time when patients received additional/alternative treatments or were considered out of study.